abl overexpress and in cells, which gives a mutant bcr abl variant partial resistance to imatinib. In vitro experiments have shown that cells that Bcr Abl variant His396Pro sensitive to a state imatinib reduction Bcr Abl protein returned SB-715992 Ispinesib to specific siRNA breakpoint c. Treatment Strategies 2007 The Behandlungsm opportunities Currently for chronic phase CML include hydroxyurea, interferon ? Interferon ? ?? ? ?p read cytarabine, imatinib, dasatinib and allogeneic SCT. Nilotinib is currently approved in Switzerland, but should also in other L Change in the very near future are available. Allogeneic stem cell transplantation has been the only Behandlungsm Possibility offer cognitive challenge cure in approximately 50 patients for whom the procedure.
However, the risks of treatment clearly outweigh the risk of disease progression after treatment with imatinib. Imatinib 400 mg t Possible is well tolerated Possible and significantly h from Than any other treatment up to 6 years of observation. I hope to finish this A66 in an excellent long-term results, but so far, followed by imatinib is not sufficient to fi rm conclusions about the year 10 or 20 pull-year results. prospective studies comparing 400 mg of t resembled an hour Heren dose of imatinib was introduced in order to optimize the treatment of chronic phase CML, but 400 mg per day is the current standard of care. Allogeneic stem cell first line can still be an option only for very young patients have unfavorable disease characteristics.
Of course, the response to imatinib and reps Possibility of treatment fa be monitored Reasonable one. The defi nition of a correct response h hangs from the size S the rebate to a few minutes after the start of treatment. These specific recommendations were issued c. Also be closely monitoring not always detect early relapse, some patients progress directly to the accelerated phase or blast crisis, and complete cytogenetic response. Defi nition of the response, treatment failure, suboptimal response, and recommend appropriate measures Ma For patients with early chronic phase CML with imatinib 400 mg per day were treated by Baccarani et al reported in 2006. A completely h’s full hematological response is defi ned as follows: platelet count 450 ? ?? ? 09 L, WBC 10 ? ?? ? 09 L, differential without immature granulocytes and with less than 5 basophils, spleen not palpable.
Top H height of cytogenetic classification ed as follows, dependent on the morphological ngig cytogenetic analysis of 20 bone marrow metaphases: Complete ? CGR Ph 0 partial or large en CGR January 35 ? Ph CGR smaller ? 36 65 Ph minimum CGR ? 66 95 Ph not ? CGR Ph 95 Molecular response was evaluated in the peripheral blood and a completely’s Full MolR Bcr Abl transcript shows nonquantifi power and undetectable. A significant MolR ned defined as more 3LOG Bcr Abl transcript reduction with respect to a standardized reference level Abl or Bcr-Abl ratio Ratio of 0.1. CGR completely’s Full and MolR important confidence on two other occasions rmed. In case of failure or suboptimal response, the options either increasing the dose of imatinib, dasatinib, experimental TK inhibitors, allogeneic stem cell transplantation or interferon ? If m resembled Allogeneic SCT s